Happy Lunar New Year from the USC US-China Institute!
Exploring China: Legal, Regulatory, and Cultural Aspects
The USC International Center for Regulatory Science is pleased to announce our second regulatory science symposium of 2014: "Exploring China: Legal, Regulatory, and Cultural Aspects”.
When:
November 1, 2014 9:00am to 5:00pm
Where
China poses both enormous economic potential and uncertain business risk for the biomedical industry that would like to tap into its expanding economy, aging population and growing talent pool. Its rapid rise in GDP, establishment of social infrastructure, and efforts to incentivize domestic R&D continue to attract companies to invest in the market and explore opportunities amidst rapidly changing environment.
This one-day symposium will feature speakers from industry, academia, and government to present current developments, issues, and challenges facing the biomedical industry in China.
Agenda Highlights:
- China’s Role in Biomedical Industry: Past, Present, and Future
- Pharmaceutical Regulation
- Medical Device Regulation
- Health System and Policy
- Medical Insurance Systems in China
- Medical Device Evaluation
- Innovation and Start-ups
- Practical Aspects of Chinese Law
- Intellectual Property Considerations
Featured speakers include:
- Dan Harris, JD, Harris Moure, Seattle, Washington
- Helen Niu, MD, PhD, Head, Senior Director, China Clinical Development of Allergan, Beijing, China
- Annie Yin, DBA, Regulatory Affairs Director, Medtronic Inc., Beijing, China
Cost:
Industry Professionals registration – $149; Networking Dinner, after the Symposium – $50
Featured Articles
January 4, 2024
We note the passing of many prominent individuals who played some role in U.S.-China affairs, whether in politics, economics or in helping people in one place understand the other.
Events
Thursday, March 21, 2024 - 4:00pm PST
Ying Zhu looks at new developments for Chinese and global streaming services.
Tuesday, March 19, 2024 - 4:00pm
David Zweig examines China's talent recruitment efforts, particularly towards those scientists and engineers who left China for further study. U.S. universities, labs and companies have long brought in talent from China. Are such people still welcome?